How does Pemvidutide work?
GLP-1 + glucagon dual agonist with structural design favoring liver-fat reduction alongside weight loss, making it a NASH/MASH candidate as well as obesity. In plain terms, Pemvidutide is altimmune's GLP-1 + glucagon dual agonist. Phase 2 data shows weight loss alongside meaningful liver-fat reduction (NASH/MASH applications). Direct competitor to Retatrutide and Survodutide. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Trial participants in NASH/MASH or obesity studies
- Patients with metabolic-syndrome plus liver involvement
- Followers of Altimmune's pipeline
References
- Pemvidutide for the treatment of NAFLD/NASH, Phase 1b — Altimmune Phase 1b readout, 2023
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study — Harrison SA et al., Journal of Hepatology, 2025
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis — Noureddin M et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pemvidutide
Last updated 2026-06-06.